Seelos Therapeutics (OTCPK:SEEL) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

SEEL 주식 개요

임상 단계의 바이오 제약 회사인 Seelos Therapeutics는 중추신경계 및 기타 질환 치료를 위한 치료제 개발 및 상용화에 주력하고 있습니다.

SEEL 기본 분석
눈송이 점수
가치 평가	1/6
미래 성장	0/6
과거 실적	2/6
재무 상태	0/6
배당금	0/6

보상

주가수익률( 0.3 x)이 US 시장( 17.6 x)보다 낮습니다.

올해부터 흑자전환

위험 분석

의미 있는 시가총액이 없습니다. ( $2M )

부채는 영업현금흐름으로 충분히 감당되지 않습니다.

마이너스 주주 지분

지난 1년 동안 주주가 크게 희석되었습니다.

+ 3 더 많은 위험

Seelos Therapeutics, Inc. 경쟁사

Evofem Biosciences

OTCPK:EVFM

US$948.1k

CannaPharmaRX

OTCPK:CPMD

US$6.5m

Kiora Pharmaceuticals

NasdaqCM:KPRX

US$10.1m

Kaya Holdings

OTCPK:KAYS

US$909.1k

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Seelos Therapeutics
과거 주가
현재 주가	US$1.19
52주 최고치	US$848.64
52주 최저치	US$0.82
베타	1.85
11개월 변경	-66.94%
3개월 변경 사항	-86.38%
1년 변경 사항	-99.83%
33년 변화	-99.99%
5년 변화	-99.97%
IPO 이후 변화	-99.99%

최근 뉴스 및 업데이트

Recent updates

주주 수익률

	SEEL	US Pharmaceuticals	US 마켓
7D	-51.8%	0.8%	1.2%
1Y	-99.8%	21.9%	35.4%

수익률 대 산업: SEEL 지난 1년 동안 17.4 %를 반환한 US Pharmaceuticals 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: SEEL 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is SEEL's price volatile compared to industry and market?
SEEL volatility
SEEL Average Weekly Movement	32.1%
Pharmaceuticals Industry Average Movement	9.4%
Market Average Movement	6.2%
10% most volatile stocks in US Market	14.7%
10% least volatile stocks in US Market	3.0%

안정적인 주가: SEEL 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: SEEL 의 주간 변동성은 지난 1년 동안 24% 에서 30% 로 증가했습니다.

회사 소개

설립	직원	CEO	웹사이트
2016	8	Raj Mehra	seelostherapeutics.com

임상 단계의 바이오 제약 회사인 Seelos Therapeutics는 중추 신경계 및 기타 장애 치료를 위한 치료제 개발 및 상용화에 주력하고 있습니다. 주요 우울 장애 환자의 급성 자살 충동 및 행동 치료를 위한 비강 내 라세믹 케타민인 SLS-002와 유전자 및 알파 시누클레인을 표적으로 하는 유전자 치료제인 SLS-004가 회사의 주요 프로그램입니다; 근위축성 측삭 경화증 및 산필리포 증후군 치료를 위한 단백질 안정제인 SLS-005, NACore 파킨슨병에 대한 펩티드 억제제인 SLS-007, 알츠하이머병에 대한 단백질 표적 자가포식제인 SLS-009. 는 2016년에 설립되었으며 미국 뉴욕에 본사를 두고 있습니다.

Seelos Therapeutics, Inc. 기본 사항 요약

Seelos Therapeutics 의 수익과 매출은 시가총액과 어떻게 비교하나요?
SEEL 기본 통계
시가총액	US$518.79k
수익(TTM)	US$4.09m
수익(TTM)	US$2.01m

0.1x

P/E 비율

0.3x

P/S 비율

SEEL 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
SEEL 손익 계산서(TTM)
수익	US$2.01m
수익 비용	US$20.45m
총 이익	-US$18.43m
기타 비용	-US$22.53m
수익	US$4.09m

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	9.38
총 마진	-915.34%
순이익 마진	203.13%
부채/자본 비율	-35.9%

SEEL 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

SEEL 주식 개요

보상

위험 분석

Seelos Therapeutics, Inc. 경쟁사

OTCPK:EVFM

US$948.1k

OTCPK:CPMD

US$6.5m

NasdaqCM:KPRX

US$10.1m

OTCPK:KAYS

US$909.1k

가격 내역 및 성능

최근 뉴스 및 업데이트

Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from NASDAQ Composite Index

Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering.

Seelos Therapeutics, Inc., Annual General Meeting, Sep 27, 2024

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $1.136948 million.

Seelos Therapeutics Announces 1-for-8 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of $1.00 Per Share of Common Stock for Continued Listing on the Nasdaq Capital Market

Recent updates

Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from NASDAQ Composite Index

Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering.

Seelos Therapeutics, Inc., Annual General Meeting, Sep 27, 2024

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $1.136948 million.

Seelos Therapeutics Announces 1-for-8 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of $1.00 Per Share of Common Stock for Continued Listing on the Nasdaq Capital Market

Nasdaq to Delist Common Stock of Seelos Therapeutics

Nasdaq to Delist Common Stock of Seelos Therapeutics

Seelos Therapeutics, Inc. Announces Appointment of Richard Pascoe as Chairman of the Board of Directors

New major risk - Market cap size

Seelos Therapeutics, Inc. Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis Study with SLS-005 (IV Trehalose)

New major risk - Revenue and earnings growth

New major risk - Market cap size

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $4.000001 million.

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $4.000001 million.

Consensus EPS estimates upgraded to US$0.41 loss

Seelos Therapeutics, Inc. Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002

Chief Financial Officer recently bought US$100k worth of stock

New major risk - Market cap size

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering.

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering.

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Consensus EPS estimates upgraded to US$0.34 loss

Seelos Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

Seelos Therapeutics Receives Non-Compliance Notice From Nasdaq

New major risk - Revenue and earnings growth

Consensus revenue estimates decrease by 26%

Seelos Therapeutics, Inc. Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide

Consensus revenue estimates increase by 80%, EPS downgraded

Seelos Therapeutics, Inc. Announces the Close of Enrollment of Its Registration Directed Study of Sls-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior (Asib) in Adults with Major Depressive Disorder (MDD)

Listing Qualifications Staff of Nasdaq Provides Notice to Seelos Therapeutics for Not Regain Compliance with Rule 5550(a)(2) and Not Eligible for Second 180 Calendar Day Compliance Period

Price target decreased by 12% to US$5.50

No longer forecast to breakeven

Seelos Therapeutics Announces Completion of Enrollment of its Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform

Seelos Therapeutics Doses First Patients in an Ethnobridging Study with Sls-002 (Intranasal Racemic Ketamine)

Seelos Therapeutics, Inc. Announces Data Demonstrating Downregulation of Alpha Synuclein in an In Vivo Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Parkinson's Disease

Seelos Therapeutics Receives Written Notice of Non-Compliance from Nasdaq

Price target decreased to US$5.80

Seelos Therapeutics Doses First Patient in A Registrational Phase II/III Study of SLS-005 in Spinocerebellar Ataxia

Seelos: Data This Year Is Critical

Seelos Therapeutics Inc. Receives A Research and Development Grant from the Michael J. Fox Foundation for Parkinson's Research for SLS-004

Seelos wins Parkinson’s research grant for gene therapy program

Seelos Therapeutics, Inc. Announces Data Demonstrating Statistically Significant Downregulation of mRNA and Reduction of Alpha Synuclein in Vitro Gene Therapy Study

Seelos Therapeutics, Inc. Receives Notice of Allowance in U.S. for an Additional Patent for SLS-007

Price target decreased to US$4.25

Seelos Therapeutics Receives Written Notice from The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

Seelos Therapeutics, Inc., Annual General Meeting, May 20, 2022

Founder recently bought US$57k worth of stock

Price target decreased to US$6.83

Seelos Therapeutics, Inc. Announces Dosing of the First Participants in a Registrational Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform

Seelos: FDA Action Makes It Highly Attractive

Seelos Therapeutics, Inc. announced that it has received $20 million in funding from The Lind Partners, LLC

High number of new and inexperienced directors

High number of new and inexperienced directors

Seelos Therapeutics: Shares Have Finally Found A Floor But Risk Remains

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors